StackTerminal.Health

BETA

NAD+

Nicotinamide adenine dinucleotide precursor supplementation to support cellular energy metabolism & longevity pathways.

goal:longevity-metabolic-cardiovasculargoal:longevitygoal:healthspangoal:metabolicconstraint:drug-test-safeevidence:moderatestudy:rctpop:general-healthy-adultsform:other
Evidence last reviewed: 04 Apr 2026
Buy this ingredient← Back
Supplement note
Private note on this supplement

Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.

Sign in to keep a private note on NAD+.
Sign in
Evidence
3 records
NAD+ precursor biology & bioavailability in human tissue
General adults; review of human studies • Systematic review / mechanistic review
PUBMEDModerate

Supports precursor-to-NAD biology; NR & NMN reliably raise blood NAD+ levels in humans, but whether NAD+ product supplementation (as opposed to precursors) is bioequivalent remains unclear. Evidence does not necessarily establish NAD+ product equivalence.

Dose: —
Citation: Nanga et al. 2024. PMC11436296.
Key mechanistic reference for NAD+ precursor biology.
NAD+ metabolome & aging in humans (NR supplementation)
Healthy adults; aging cohorts • Randomized controlled trial
PUBMEDModerate

Nicotinamide riboside (NR) supplementation significantly increased whole-blood NAD+ & related metabolites; effects on downstream aging biomarkers were modest & variable across individuals.

Dose: —Form: Nicotinamide Riboside
Citation: Berven H, et al. A randomized, placebo-controlled study of the effects of nicotinamide riboside on energy metabolism, muscle function, and physical performance in healthy adults. Nat Commun. 2023.
Nat Commun 2023; doi verified.
Blood NAD+ elevation & physical performance (NMN supplementation)
Healthy middle-aged adults (n=80) • Randomized, multicenter, double-blind, placebo-controlled, dose-dependent clinical trial
PUBMEDModerate

NMN at 300, 600, or 900 mg/day for 60 days significantly increased blood NAD+ vs placebo (p≤0.001). Six-minute walk distance improved significantly at 600–900 mg. Biological age remained stable in NMN groups while increasing in placebo. Well tolerated with no adverse events.

Dose: 600 mgDuration: 60 days
Citation: Yi L, Maier AB, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023;45(1):29-43.
Dose-dependent NAD+ elevation; clinical significance of performance improvements needs replication in larger trials.

Stacks containing NAD+

Public community stacks that include this ingredient.

Explore all stacks →
No public stacks include this ingredient yet.